Bicara Q3 Loss Widens to $71.2M; $442.3M Cash Funds Operations Into 1H 2029
BCAX is trading near its 52-week low of $7.87 (9.9% above the low).
Summary
Bicara reported a wider Q3 2026 loss of $71.2M as trial and commercialization spending ramped, while $442.3M in cash extends its runway into the first half of 2029 — past the mid-2027 interim data from its pivotal head and neck cancer trial.
Updates
· Reuters — Bicara Therapeutics reported a quarterly adjusted loss of $1.04 per share for the quarter ended September 30, versus the mean expectation of fourteen analysts for a loss of 83 cents per share.
- Reported revenue was zero; analysts expected zero.
- Quarterly net loss: $71.25 million.
Key Events · Earnings and Guidance · BCAX
-
Q3 Loss Widens on Trial Spend
Net loss was $71.2M ($1.04 per share) versus $36.3M ($0.67) in Q3 2025, driven by R&D of $56.5M (up from $33.0M) and G&A of $19.2M (up from $7.7M).
-
Cash Runway Extended to 1H 2029
Cash, equivalents and marketable securities totaled $442.3M at September 30, 2026, up from $414.8M at December 31, 2025, funding operations into the first half of 2029.
-
Pivotal Trial Fully Enrolled
Bicara achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC, with topline interim results expected mid-2027.
-
Alternate Dosing Study Enrolling
FORTIFI-FLEX is testing a 12-week 1500mg weekly loading dose followed by 2250mg every three weeks versus 1500mg weekly, each with pembrolizumab; data expected by potential U.S. approval.
Analysis · BCAX · Life Sciences
The balance sheet is the story here: $442.3M in cash and securities carries Bicara into the first half of 2029, past the mid-2027 interim readout that will decide the program's value. The loss widened sharply as the company spends to run its pivotal head and neck cancer trial and build a commercial team. Investors are paying for that readout, so the key question is whether spending at this pace holds through the data. No financing is needed near term, which removes the dilution overhang that usually hangs over clinical-stage names.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCAX was trading at $8.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $572.4M. The 52-week trading range was $7.87 to $30.99. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.